Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
Fred Hutchinson CTD2 researchers identified novel therapeutic targets for precision oncology using high-throughput functional phenotyping with siRNA and drug libraries in primary patient derived head and neck cancer cells.
Expression analysis reveals pan-cancer and tumor-specific MYC-associated pathways. Integrating these analysis results with the TCGA dataset could provide insights in understanding MYC-driven cancers and identify novel markers and therapeutic approaches for cancer treatments.
An automated decision tree genetic abnormalities analyses is used to stratify acute myeloid leukemia patients according to the European Leukemia Network guidelines.
This study by TARGET researchers analyzed DNA changes and sequenced the genomes, exomes, and transcriptomes of 1,699 pediatric leukemia and solid tumors. Out of the 142 genes associated with cancer in these pediatric patients, only 45% matched those found in similar studies of adult cancers.
CTD2 scientists at the University of Texas MD Anderson Cancer Center demonstrated inhibition of bromodomain-containing four induced homologous recombination deficiencies. This inhibition resensitizes cells with acquired resistance to PARP inhibitors.
UTMDACC developed a functional genomic platform used to annotate gene amplifications, point mutations, indels, and gene fusions of cancer variants. This data is accessible through a user-friendly, interactive open-access web portal, FASMIC (Functional Annotation of Somatic Mutations in Cancer).